On April 22, 2025 NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, reported the analytical validation of its PanTracer LBx assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling (Press release, NeoGenomics Laboratories, APR 22, 2025, View Source [SID1234652035]). The validation study, along with five additional abstracts, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 in Chicago, April 25–30.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PanTracer LBx is a blood-based test that analyzes circulating tumor DNA to identify key genomic alterations in patients with advanced-stage solid tumors. It is designed to support treatment decisions when tumor tissue is unavailable or insufficient—a common challenge in oncology care. In the validation study, PanTracer LBx demonstrated high performance in identifying key biomarkers—including MSI (microsatellite instability) and TMB (tumor mutational burden)—across multiple cancer types, reinforcing its potential to guide therapy selection and expand access to precision oncology. The poster, "Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay," will be presented on Tuesday, April 29, from 9 AM – 12 PM CT, Section 10, Poster 27.
NeoGenomics has also launched an Evaluation Assessment Program for PanTracer LBx, allowing select physicians to use the assay ahead of full commercial availability. The program is intended to identify opportunities to streamline logistics, reporting, and customer support.
"The clinical validation of PanTracer LBx is the result of extensive analytical testing and represents a meaningful addition to our specialized testing menu designed to serve our community oncologists," said Andrew A. Lukowiak, Ph.D., Chief Innovation Officer at NeoGenomics. "Our presence at AACR (Free AACR Whitepaper) reflects a deep commitment to advancing the accessibility of cutting-edge oncology diagnostics and developing practical, real-world solutions that support patients and providers alike."
The company will present five additional posters that span topics such as spatial profiling, tumor biology, and genomic co-occurrence, including:
Characterization of GM-CSF and G-CSF expressing cell subtypes in the tumor microenvironment using the Integrated MultiOmyx-RNAscope assay
April 28, 2:00 PM – 5:00 PM, Section 7, Poster 30
Accurate, high-throughput spatial profiling of whole slide samples with the NeoLYTX pipeline
April 28, 9:00 AM – 12:00 PM, Section 46, Poster 29
High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection
April 28, 9:00 AM – 12:00 PM, Section 1, Poster 14
Co-occurrence of gene fusions with SNV/Indels and with CNVs on solid tumors in a cohort of 795 patients from the community setting
April 28, 2:00 PM – 5:00 PM, Section 31, Poster 27
Comprehensive characterization of renal cell carcinomas identifies metabolic reprogramming of the tumor microenvironment associated with disease progression
April 29, 2:00 PM – 5:00 PM, Section 12, Poster 10
NeoGenomics will also showcase its oncology diagnostics solutions at booth #2449.